Marc Dunoyer (AstraZeneca via YouTube)
On the back of PhIII success, AstraZeneca lays out the red carpet for rare disease drug Alexion paid $855M for
When Ludwig Hantson gambled $855 million to buy out Wilson Therapeutics back in 2018, the CEO framed it as the first step of rebuilding …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
